• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Deep Dive into the Use of Real-World Registry Data as External Control Arms


While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.

Watch this video and learn more:

  • Challenges faced by biopharma companies conducting clinical trials when studying rare conditions.
  • The purpose of a control population in traditional randomized controlled clinical trials.
  • How hybrid control arms can improve the strength of control groups.
  • How prospective registries serve as real-world control populations.
  • How to minimize bias between populations or outcome measures across RCT control groups vs. real-world/hybrid controls.

Related Videos
Jason Tate, FSP Talent Strategy Lead, PPD, part of Thermo Fisher Scientific